Abstract
We have shown that inhibition of WT1/+17AA protein expression following transfection with a vector-based small interfering RNA expression construct in K562 cell lines, leads to a decrease in MDR1 and P-glycoprotein levels, accumulation of Rh123, and enhancement of the doxorubicin cytotoxicity. Our findings suggest that WT1/+17AA exerts its oncogenic function by modulating multidrug resistance in leukemia cells.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B / metabolism
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
-
Antibiotics, Antineoplastic / pharmacology
-
Down-Regulation
-
Doxorubicin / pharmacology
-
Drug Resistance, Multiple*
-
Drug Resistance, Neoplasm*
-
Humans
-
K562 Cells / metabolism
-
Leukemia / drug therapy*
-
Leukemia / genetics
-
Leukemia / metabolism*
-
Polymerase Chain Reaction
-
RNA, Small Interfering / pharmacology
-
Rhodamine 123 / metabolism
-
WT1 Proteins / antagonists & inhibitors
-
WT1 Proteins / genetics
-
WT1 Proteins / metabolism*
Substances
-
ATP Binding Cassette Transporter, Subfamily B
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Antibiotics, Antineoplastic
-
RNA, Small Interfering
-
WT1 Proteins
-
Rhodamine 123
-
Doxorubicin